Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.45 |
| ▸ | LIPE | Q05469 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739758 | 0.86 | SCN9A (0.51) | ABHD6SCN9ALIPEMAPTUCHL1 | |
| SCHEMBL17021259 | 0.86 | SCN9A (0.51) | ABHD6SCN9ALIPEMAPTUCHL1 | |
| SCHEMBL28107776 | 0.82 | SCN9A (0.59) | ABHD6SCN9ABTKNAMPTUCHL1 | |
| SCHEMBL1550533 | 0.79 | UCHL1 (0.53) | ABHD6BTKLMNAHTTUCHL1 | |
| SCHEMBL17010302 | 0.78 | ABHD6 (0.56) | ABHD6SCN9ABTKUCHL1 | |
| SCHEMBL22853551 | 0.78 | SCN9A (0.76) | SCN9AHDAC11LMNAHTT | |
| SCHEMBL17010303 | 0.76 | ABHD6 (0.54) | ABHD6SCN9ABTKHTTSMN1; SMN2 | |
| SCHEMBL15271709 | 0.74 | SCN9A (0.55) | ABHD6SCN9ABTKSCN5A | |
| SCHEMBL15272252 | 0.74 | SCN9A (0.60) | ABHD6SCN9ASCN5A | |
| SCHEMBL2354750 | 0.73 | ABHD6 (0.54) | ABHD6SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| CN-106103422-B | Isoquinoline derivatives and uses thereof | 普渡制药公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10738026-B2 | Isoquinoline derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-03-02 | — | — | US | disclosed |
| EP-3105217-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123398-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738026-B2 | Isoquinoline derivatives and use thereof | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885LIPE 4638/4885 |
| US-20170057942-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885LIPE 4638/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | ABHD6 3395/4885SCN9A 67/4885LIPE 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.